JPRN-UMIN000029205已完成未知
Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe Obesity - Effects of Dapagliflozin on Body Composition
Jinnouchi Hispital0 个研究点目标入组 60 人开始时间: 2017年12月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •severe obesity (BMI>35) Type 1 DM ketoacidosis unstable clinical conditions active infection, liver disease, cancer eGFR<45
研究者
相似试验
已完成
2 期
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424DiabetesNL-OMON48616Radboud Universitair Medisch Centrum15
进行中（未招募）
1 期
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesEUCTR2018-001569-17-NLRadboud university medical center15
进行中（未招募）
不适用
Impact of treatment with Dapagliflozin in type 1 diabetic patientsType 1 diabetesEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
尚未招募
不适用
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
招募中
不适用
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20